Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

762
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
762
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

622
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
622
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

474
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
474
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

533
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
533
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Patient-Centered Outcome Tool for Blepharospasm: A Stepwise Modified Delphi Study.

Toxins·2025
Same author

Diagnostic accuracy of screening tools for depression and anxiety in cervical dystonia.

Parkinsonism & related disorders·2025
Same author

Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm.

Parkinsonism & related disorders·2024
Same author

Tremor in cervical dystonia.

Dystonia (Lausanne, Switzerland)·2024
Same author

External Factors Modulating Pain and Pain-Related Functional Impairment in Cervical Dystonia.

Movement disorders clinical practice·2024
Same author

Parkinson's disease cerebrovascular reactivity pattern: A feasibility study.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2024
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Sep 13, 2025

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.5K

Dystonia.

Sarah Pirio Richardson

    Continuum (Minneapolis, Minn.)
    |August 1, 2025
    PubMed
    Summary
    This summary is machine-generated.

    Dystonia is a complex movement disorder. Early recognition of its signs and symptoms is crucial for accurate diagnosis and effective treatment, including new therapies and managing nonmotor symptoms.

    More Related Videos

    Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
    10:05

    Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

    Published on: January 27, 2018

    9.9K
    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
    05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    4.0K

    Related Experiment Videos

    Last Updated: Sep 13, 2025

    Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
    10:41

    Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

    Published on: September 12, 2020

    7.5K
    Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
    10:05

    Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

    Published on: January 27, 2018

    9.9K
    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
    05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    4.0K

    Area of Science:

    • Neurology
    • Movement Disorders

    Background:

    • Dystonia is a heterogeneous movement disorder that can be a primary condition or secondary to other neurological diseases.
    • Accurate diagnosis is challenging due to the absence of specific biomarkers, emphasizing the importance of clinical recognition.

    Purpose of the Study:

    • To review the epidemiology, diagnostic criteria, clinical features, and treatment of dystonia.
    • To discuss current controversies and emerging aspects in dystonia management.

    Main Methods:

    • Literature review focusing on epidemiology, diagnosis, clinical presentation, and therapeutic options for dystonia.
    • Analysis of recent advancements in classification and treatment modalities.

    Main Results:

    • Dystonia diagnosis relies on careful clinical evaluation and recognition of characteristic signs.
    • Therapeutic landscape includes neurostimulation and botulinum toxin injections, with growing attention to nonmotor symptoms like pain and mood disorders.

    Conclusions:

    • Accurate and timely diagnosis of dystonia is paramount for effective management.
    • The evolving understanding of dystonia necessitates updated classification systems and comprehensive treatment strategies addressing both motor and nonmotor aspects.